Rallybio Corporation Company Profile
NASDAQ: RLYBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Rallybio at a glance
Rallybio Corporation (NASDAQ: RLYB) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in New Haven, CT. Rallybio is led by Dr. Stephen Uden M.D., MBBS and employs about 7 people. The company's shares have traded publicly since 2021.
At a market capitalization of $90.2 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001739410, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Rallybio do?
Rallybio Corporation, a clinical-stage biotechnology company, engages in the development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is the RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB332, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. The company has a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases, as well as collaboration agreement with Johnson & Johnson to provide therapeutic solutions for pregnant individuals at risk of fetal and neonatal alloimmune thrombocytopenia. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut.
Business description based on the company's public filings.
Company information
- Legal name
- Rallybio Corporation
- Ticker
- NASDAQ: RLYB
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Stephen Uden M.D., MBBS
- Employees
- 7
- Headquarters
- 234 Church Street, New Haven, CT, United States
- Phone
- 203 859 3820
- Website
- rallybio.com
- IPO year
- 2021
- Market cap
- $90.23M
- SEC CIK
- 0001739410
- Latest annual report
- 10-K · Mar 16, 2026
Companies similar to Rallybio
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EQEquillium Inc. | 1.41 | -2.08% | $89.41M | vs RLYB |
| CTORCitius Oncology Inc. | 0.8398 | +0.57% | $88.82M | vs RLYB |
| PMNProMIS Neurosciences Inc. | 9.61 | +5.03% | $86.18M | vs RLYB |
| MISTMilestone Pharmaceuticals Inc. | 0.765 | +7.43% | $95.24M | vs RLYB |
| RFLRafael Holdings Inc. Class B | 1.60 | +8.11% | $83.20M | vs RLYB |
| OKUROnKure Therapeutics Inc. Class A | 2.41 | +4.78% | $97.60M | vs RLYB |
| TELOTelomir Pharmaceuticals Inc. | 1.12 | -2.61% | $82.45M | vs RLYB |
| ZYBTZhengye Biotechnology Holding Limited Class A | 1.73 | +50.45% | $81.99M | vs RLYB |